Sai-Juan Chen
Overview
Explore the profile of Sai-Juan Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
7336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Gui T, Jiao B, Liu X, Ma X, Wang C, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(7):e2423169122.
PMID: 39946534
Acute lymphoblastic leukemia (ALL) poses challenges in adult patients, considering its heterogeneous nature and often suboptimal treatment outcomes. Here, we performed a study on 201 newly diagnosed adult ALL cases...
2.
Pagliaro L, Chen S, Herranz D, Mecucci C, Harrison C, Mullighan C, et al.
Nat Rev Dis Primers
. 2024 Jun;
10(1):41.
PMID: 38871740
Acute lymphoblastic leukaemia (ALL) is a haematological malignancy characterized by the uncontrolled proliferation of immature lymphoid cells. Over past decades, significant progress has been made in understanding the biology of...
3.
Yu P, Hou D, Chang B, Liu N, Xu C, Chen X, et al.
Dev Cell
. 2024 May;
59(15):1954-1971.e7.
PMID: 38776924
A significant variation in chromatin accessibility is an epigenetic feature of leukemia. The cause of this variation in leukemia, however, remains elusive. Here, we identify SMARCA5, a core ATPase of...
4.
Xu J, Wang B, Yu S, Chen S, Yang S, Liu R, et al.
J Hematol Oncol
. 2024 Apr;
17(1):23.
PMID: 38659046
Background: The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across...
5.
Tian J, Song Y, Zhang G, Wang S, Chu X, Chai Y, et al.
J Cancer Res Clin Oncol
. 2024 Apr;
150(4):189.
PMID: 38605258
Purpose: The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the...
6.
Li J, Cheng W, Lin X, Wen L, Wang K, Zhu Y, et al.
Proc Natl Acad Sci U S A
. 2024 Feb;
121(10):e2319366121.
PMID: 38422020
Acute myeloid leukemia (AML) is an aging-related and heterogeneous hematopoietic malignancy. In this study, a total of 1,474 newly diagnosed AML patients with RNA sequencing data were enrolled, and targeted...
7.
Yang S, Xu J, Dai Y, Jin S, Sun Y, Li J, et al.
Nat Commun
. 2024 Jan;
15(1):360.
PMID: 38191582
Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime...
8.
Sun Y, Yang X, Yang S, Lyu Y, Zhang B, Liu K, et al.
Signal Transduct Target Ther
. 2023 Dec;
8(1):445.
PMID: 38062078
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane. However, cell-surface antigen-induced multimerization...
9.
Xiong J, Dai Y, Wang W, Zhang H, Wang C, Yin T, et al.
Sci Bull (Beijing)
. 2023 Oct;
68(21):2607-2619.
PMID: 37798178
Epstein-Barr virus (EBV) is the oncogenic driver of multiple cancers. However, the underlying mechanism of virus-cancer immunological interaction during disease pathogenesis remains largely elusive. Here we reported the first comprehensive...
10.
Zhang M, Tian S, Fu D, Wang L, Cheng S, Yi H, et al.
Cancer Cell
. 2023 Sep;
41(10):1705-1716.e5.
PMID: 37774697
We report the results of GUIDANCE-01 (NCT04025593), a randomized, phase II trial of R-CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subtyping of newly diagnosed, intermediate-risk, or...